Targeting p53 for enhanced radio- and chemo-sensitivity
- 4 March 2009
- journal article
- review article
- Published by Springer Nature in Apoptosis
- Vol. 14 (4) , 597-606
Abstract
P53 acts as a central mediator of the cellular response to stressful stimuli. The growth-suppressive function of p53 is lost with mutation and this occurs commonly in human cancer. In addition to suppressing cancer development and progression, wild-type p53 further confers chemo-sensitivity and radio-sensitivity upon tumor cells. Accumulated evidence over the last two decades that wild-type p53 activity is required for the efficacy of radiation and chemotherapy has led to considerable interest in development of strategies to restore normal p53 function in tumors with defective p53-dependent signaling. A number of promising discoveries, based on the knowledge of structural and functional basis of p53 mutation, p53 degradation by MDM2 and p53 family proteins, provide a foundation for future drug design. Here we review the role of p53 in enhancing the sensitivity from radiation and chemotherapy and discuss current progress on therapies targeting p53.Keywords
This publication has 117 references indexed in Scilit:
- MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2Leukemia, 2008
- PACT is a negative regulator of p53 and essential for cell growth and embryonic developmentProceedings of the National Academy of Sciences, 2007
- Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenograftsProceedings of the National Academy of Sciences, 2006
- Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- Post-translational modification of p53 in tumorigenesisNature Reviews Cancer, 2004
- Targeting the p53–MDM2 interaction to treat cancerBritish Journal of Cancer, 2004
- The ubiquitin ligase COP1 is a critical negative regulator of p53Nature, 2004
- DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 2003
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002